|
| Study ID | Study phase | Treatment | Population | Status |
|
| NCT02901301 | Ib/II | Pembrolizumab + trastuzumab + cisplatin + capecitabine | HER2 positive advanced gastric cancer | Recruiting |
|
CP-MGAH22-05
(NCT02689284) | Ib/II | Margetuximab in combination with pembrolizumab | Relapsed/refractory advanced HER2+ GEJ or gastric cancer | Recruiting |
| NCT02318901 | Ib/II | Pembrolizumab and monoclonal antibody therapy | Patients with advanced cancer (one cohort for patients with unresectable HER2 overexpressing gastric or GEJ cancers) | Active, not recruiting |
| NCT03095781 | Ib | Pembrolizumab and XL888 | Patients with stage IV or locally advanced unresectable gastrointestinal adenocarcinomas who have failed at least one prior therapy | Recruiting |
|
| NCT02178722 | I/II | Pembrolizumab in combination with epacadostat | Patients with selected cancers (including gastric cancer) | Recruiting |
|
| NCT03342937 | II | Pembrolizumab + oxaliplatin and capecitabine | First-line treatment of patients with gastroesophageal cancer | Not yet recruiting |
|
| NCT02954536 | II | Pembrolizumab in combination with trastuzumab, capecitabine/cisplatin | First-line stage IV HER2-positive metastatic esophagogastric (EG) cancer | Recruiting |
|
| NCT03196232 | II | Epacadostat and pembrolizumab | Metastatic or unresectable GEJ or gastric cancer that progressed at least first line of prior therapy | Recruiting |
|
KEYNOTE KN-463
(NCT03122548) | II | CRS-207 and pembrolizumab | Recurrent or metastatic gastric, GEJ, or esophageal cancer who have received 2 prior systemic chemotherapy treatment | Recruiting |
|
KEYNOTE-063
(NCT03019588) | III | Pembrolizumab versus paclitaxel | Asian subjects with advanced gastric or GEJ adenocarcinoma who progressed after first-line therapy with platinum and fluoropyrimidine | Recruiting |
|
KEYNOTE-062
(NCT02494583) | III | Pembrolizumab as monotherapy and in combination with cisplatin + 5-fluorouracil versus placebo + cisplatin + 5-fluorouracil | As first-line treatment in subjects with advanced gastric or GEJ adenocarcinoma | Active, not recruiting |
|
KEYNOTE-061
(NCT02370498) | III | Pembrolizumab versus paclitaxel | Advanced gastric or GEJ adenocarcinoma who progressed after first-line therapy with platinum and fluoropyrimidine | Active, not recruiting |
|
ONO4538
(NCT02267343) | III | Nivolumab versus placebo | Unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) refractory to or intolerant of standard therapy | Active, not recruiting |
CA209-929
(NCT03342417) | II | Combination of nivolumab and ipilimumab in breast, ovarian, and gastric cancer patients | In gastric cancer arm: advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin | Recruiting |
ONO-4538-37
(NCT02746796) | II/III | Nivolumab and chemotherapy versus placebo and chemotherapy | Unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) not previously treated with the first-line therapy | Recruiting |
CheckMate 649
(NCT02872116) | III | Nivolumab plus ipilimumab or nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine | Patients with previously untreated advanced or metastatic gastric or gastroesophageal junction cancer | Recruiting |
FRACTION-GC
(NCT02935634) | II | Nivolumab plus ipilimumab versus nivolumab plus relatlimab versus nivolumab and BMS-986205 | Patients with advanced gastric cancer | Recruiting |
|
NCCH-1611
NCT02999295 | I/II | Ramucirumab plus nivolumab | Second-line therapy in Participants with gastric or GEJ cancer | Recruiting |
AIO-STO-0217
(NCT03409848) | II | Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab | Previously untreated HER2 positive locally advanced or metastatic esophagogastric adenocarcinoma | Not yet recruiting |
INCAGN 1876-201
(NCT03126110) | I/II | INCAGN01876 combined with nivolumab versus INCAGN01876 combined with ipilimumab versus INCAGN01876 combined with nivolumab and ipilimumab | Subjects with advanced or metastatic malignancies | Recruiting |
|
